Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors

Publication Date: December 5, 2016

Key Points

Key Points

Cardiac dysfunction is a serious side effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the cancer patient.

Heart failure (HF), presenting during or after completion of cancer treatment, is a well-recognized complication that begins with risk factors known to be associated with the development of HF, including the toxicity of chemotherapy and/or radiation (stage A), and is commonly progressive after structural changes to the heart occur.

The initial manifestation may be asymptomatic.

Onset may also be responsible for interruption or discontinuation of cancer-directed therapy, potentially reducing the chance for long-term survival.

Risk

...isk...

...ended that cancer patients who meet any...


...ecommendation can be made on the risk of cardi...


Prevention

...reventi...

...RIOR TO Initiation of Therapy...

...d or minimize the use of potential...

...ians should perform a comprehensive assessment in...


...tion DURING Potentially Cardiotoxic C...

...inicians should screen for and actively manage mod...

...ians may incorporate a number of str...

...ents who require mediastinal RT which might...


Surveillance

...rveillance

...g During Treatment...

...should complete a careful history...

...commendation 4.2

...iogram for diagnostic work-up ( EB , H , B...

...gnetic resonance imaging (MRI) or multi-gat...

...iomarkers (troponins, natriuretic peptides...

...l to a cardiologist based on findings....

...e surveillance imaging may be offered durin...

...ations can be made regarding conti...

...use routine echocardiographic surveillance...


...toring After Treatmen...

...ould complete a careful history and physical ex...

...ecommendation 5...

...gram for diagnostic work-up ( EB , H , B , M )...

...MUGA if echocardiogram is not available or t...

...rdiac biomarkers (troponins, natriuretic peptides)...

...l to a cardiologist based on findings (IC, B, S,...

...m may be performed 6–12 months after co...

...or MUGA may be offered for surveillance in asym...

Patients identified to have asymptomatic cardia...

...ions can be made regarding the freq...

...should regularly evaluate and manage c...